Star Therapeutics disclosed early clinical results for two programs: VGA039, an anti‑bleeding antibody with encouraging phase 1/2 data, and a once‑monthly injection for von Willebrand disease that substantially reduced bleeding rates in a preliminary study. The company has dosing underway in a pivotal Phase 3 trial for VGA039 and is considering next steps, including potential IPO plans to fund larger studies. Company executives said the Phase 1/2 safety and efficacy signals justify accelerated pivotal work. Investors and bleeding‑disorder specialists will watch registration trial design, comparator choices and durability of effect as Star seeks regulatory approvals and commercial partnerships.